Stanford inventors have developed a single cell screening platform that can be used to predict the therapeutic effects of osteoarthritis (OA) drugs on individual patients by defining consequent changes in the cellular landscape.
Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.
Researchers in Prof. Brian Feldman's laboratory have developed a patented drug screen to identify compounds that could potentially treat obesity and metabolic disease by converting cells to calorie-burning brown fat.
Researchers in Prof. Gerald Crabtree's laboratory have produced a mouse allowing high-throughput screening for activity and inhibition of virtually any chromatin modifier in any murine tissue.
Researchers in Dr. Michael Lin's lab have developed a fluorescent voltage sensor for non-invasive optical monitoring of electrical events in living cells in vitro and in vivo.